Acutaas Chemicals Q1 FY27 Revenue Surges 59.1% YoY to ₹329.7 Crore; PAT Up 70.4%
Acutaas Chemicals reported Q1 FY27 results with revenue from operations at ₹329.7 crore, up 59.1% YoY. PAT increased by 70.4% to ₹75 crore. EBITDA surged 122.1% to ₹113.1 crore. The company reaffirmed its full-year revenue growth target of 25%.
The significant double-digit growth in key financial metrics like revenue and profit, coupled with a positive outlook and reaffirmed growth targets, is expected to have a substantial positive impact on investor sentiment and the company's stock performance.
The company reported strong year-on-year growth in revenue, profit after tax, EBITDA, and improved margins, exceeding expectations and reaffirming positive future guidance.
Acutaas Chemicals Limited (formerly Ami Organics Limited) announced its financial results for the first quarter ended June 30, 2026. The company reported a significant year-on-year growth, with revenue from operations reaching ₹3,297 million (₹329.7 crore), an increase of 59.1%. Profit After Tax (PAT) also saw a substantial rise of 70.4% to ₹750 million (₹75 crore), with PAT margins at 22.7% for the quarter.
Gross profit for Q1 FY27 stood at ₹1,909 million (₹190.9 crore), up 73.0% YoY, with gross margins improving to 57.9%. EBITDA grew by an impressive 122.1% YoY to ₹1,131 million (₹113.1 crore), resulting in an EBITDA margin of 34.3% for the quarter.
Mr. Naresh Patel, Executive Chairman & Managing Director, expressed confidence in the company's performance, stating, "We have started the year on a strong note, with revenue from operations growing 59.1% YoY to Rs. 3,297 mn — reflecting the agility of our business model and our ability to keep delivering to customers, on time and without compromise." He also highlighted the company's recent certifications as a "Great Place to Work" and "Responsible Care" from the Indian Chemical Council. Acutaas Chemicals reaffirmed its full-year revenue growth target of 25% with stable margins.
What to do with a filing like this
Acutaas Chemicals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Acutaas Chemicals Limited. Read the original for the full detail.